Fig. 5From: Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysisRadar Chart comparing efficacy and toxicity of neoadjuvant combinationBack to article page
